Decisions should integrate patient preferences, tumor characteristics, prior therapy, and actionable biomarkers such as ESR1 and PIK3CA mutations, AKT pathway alterations, HER2-low/ultra-low status, and germline BRCA mutations. Here, ERBB2 is linked to neoplasm.